Login to Your Account



Adjuvant Deal with CSL

Opsona Raises €18M for Anti-TLR-2 Antibod

By Cormac Sheridan


Wednesday, February 25, 2009

No Abstract

 

BioWorld International Correspondent

DUBLIN, Ireland - Opsona Therapeutics Ltd. raised €18 million (US$23 million) in a Series B round and unveiled a research and collaboration agreement with CSL Ltd., based on the identification of novel vaccine adjuvant formulations using its proprietary OpsoVac immunotherapy platform.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription